3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
6
Carcinoid Tumor
5
Neoplasms
4
Carcinoma
3
Vipoma
2
Neoplasm Metastasis
2
Intestinal Obstruction
2
Carcinoma, Islet Cell
2
Somatostatinoma
1
Recurrence
1
Prostatic Neoplasms
1
Primary Inoperable Thymoma
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Malignant Carcinoid Syndrome
1
Lymphangiomyoma
1
Lymphangioleiomyomatosis
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Diarrhea
1
Chylous Ascites
1
Chylothorax
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Ascites
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
3
cabozantinib
2
tipifarnib
1
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
guadecitabine
1
fostamatinib
1
copper dotatate CU-64
1
atezolizumab
1
Temozolomide
1
Surgical Procedures, Operative
1
Sunitinib
1
Phenoxybenzamine
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Capecitabine
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Pheochromocytoma
×
Octreotide
×
Clear all
No trials found.